Br J Cancer: Circulating Tumor Cells (CTC) and Cell-Free DNA (cfDNA): Prognostic Targets for Metastatic Colorectal Cancer

Precision medicine is an emerging disease treatment and prevention method that takes into account individual differences in genes, environment, and life>Although this method can be used in a variety of medical fields, precision medicine is most likely to contribute to cancer treatment.
According to the patient's genetic characteristics (such as pharmacogenomics), etc.
, precise and personalized treatment plans are tailored to the patient.

Precision medicine is an emerging disease treatment and prevention method that takes into account individual differences in genes, environment, and life>Precision medicine is an emerging disease treatment and prevention method that takes into account individual differences in genes, environment, and life>Preciseprevention According to the patient's genetic characteristics (such as pharmacogenomics), etc.
, precise and personalized treatment plans are tailored to the patient.
According to the patient's genetic characteristics (such as pharmacogenomics), etc.
, tailor-made precise and personalized treatment plans for the patient.

The OMITERC prospective study (biopsy from a solid to a liquid application OMIcs biopsy, personalized treatment for cancer) is a shared data item, to develop a cancer genomics and the pharmacogenomic data KRAS mutations metastatic colorectal A dataset that links the clinical outcomes of rectal cancer (mCRC).

The aim is to develop a data set that links cancer genomics and pharmacogenomics data with the clinical outcomes of KRAS-mutated metastatic colorectal cancer (mCRC).
The aim is to develop a data set that links cancer genomics and pharmacogenomics data with the clinical outcomes of KRAS-mutated metastatic colorectal cancer (mCRC).
Colorectal cancer

In this study, the researchers explored the prognostic effects of liquid biopsy including cell-free DNA (cfDNA) and circulating tumor cells (CTC) in KRAS-mutated metastatic colorectal cancer (mCRC).

Kaplan-Meier curve to evaluate the progression-free survival (PFS) and overall survival (OS) of patients with mCRC

Kaplan-Meier curve to evaluate the progression-free survival (PFS) and overall survival (OS) of patients with mCRC

The researchers defined a pre-analysis and analysis process, including blood collection before treatment and every 3 months until disease progression (PD).
Perform NGS sequencing of CTC and cfDNA through a set of genes related to cancer/CRC.

The results showed that the mutation status of KRAS was basically the same between tumor tissue and liquid biopsy.

The percentage of cfDNA samples with CRC driver gene mutations is consistent with that reported in the literature.

Longitudinal disease monitoring of mCRC patients through liquid biopsy assessment

Longitudinal disease monitoring of mCRC patients through liquid biopsy assessment

All in all, the results of the study revealed that in mCRC, cfDNA and CTC are ready-made candidate targets that can be used in clinical applications.

Although CTC showed prognostic significance at baseline, cfDNA proved to be an easily accessible material that can be used to monitor the mutation status of tumors over time.

In mCRC, cfDNA and CTC are ready candidates for clinical applications.

org/10.

Leave a message here